IP Library Granted Patent US 9,340,537
Granted Patent B2
US 9,340,537 · App. 14/400,992 · Granted May 17, 2016

Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Inventors: Pascal Furet (Thann, FR); Robert Martin Grotzfeld (Ettingen, CH); Wolfgang Jahnke (Lorrach, DE); Darryl Brynley Jones (Basel, CH); Paul William Manley (Arlesheim, CH); Andreas Marzinzik (Weil, DE); Xavier Francois Andre Pelle (Kembs, FR); Bahaa Salem (Basel, CH); Joseph Schoepfer (Riehen, CH)
Assignee: NOVATIS AG
C07D417/14A61K31/4025A61K31/427A61K31/4439A61K31/5377A61K45/06C07D401/04C07D401/14C07D403/10C07D405/14C07D409/14C07D413/14C07D417/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,340,537
App. No.
14/400,992
Granted
May 17, 2016
Kind
B2
Abstract

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

Claims (14)

1. A compound of formula (I):

in which:

R 5 is selected from hydrogen, methoxy and imidazolyl; wherein said imidazolyl is unsubstituted or substituted with methyl;

R 1 is thiazolyl unsubstituted or substituted with 1 to 3 R 6 groups;

R 2 is selected from pyrrolidinyl unsubstituted or substituted with 2 or 3 R 7 groups;

R 3 is selected from hydrogen and halo;

R 4 is selected from —SF 5 and —Y 2 —CF 2 —Y 3 ;

R 6 at each occurrence is independently selected from hydrogen, hydroxy, methyl, hydroxy, methoxy, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl, cyclopropyl and dimethyl-amino-carbonyl;

R 7 at each occurrence is independently selected from hydroxy, methyl, halo, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, 2-amino-3-methylbutanoyl)oxy, carboxy, methoxy-carbonyl, phosphonooxy, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from cyclopropyl, azetidin-3-yl and 3-azabicyclo[3.1.0]hexan-3-yl;

Y 2 is selected from CF 2 , O and S(O) 0-2 ; and

Y 3 is selected from hydrogen, halo, methyl, difluoromethyl and trifluoromethyl;

or the pharmaceutically acceptable salts thereof.

2. The compound of claim 1 selected from:

3. A pharmaceutical composition comprising a compound of claim 1 , admixed with at least one pharmaceutically acceptable excipient selected from the group consisting of corn starch, potato starch, tapioca starch, starch paste, pre-gelatinized starch, sugars, gelatin, natural gums, synthetic gums, sodium alginate, alginic acid, tragacanth, guar gum, cellulose, ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethylcellulose, methyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium aluminum silicate, polyvinyl pyrrolidone, talc, calcium carbonate, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, agar-agar, sodium carbonate, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, clays, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, sodium lauryl sulfate, hydrogenated vegetable oil, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, soybean oil, zinc stearate, sodium oleate, ethyl oleate, ethyl laureate, silica, and combinations thereof.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 034184/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: FURET, PASCAL; GROTZFELD, ROBERT MARTIN; JONES, DARRYL BRYNLEY; MANLEY, PAUL WILLIAM; MARZINZIK, ANDREAS; PELLE, XAVIER FRANCOIS ANDRE; SALEM, BAHAA; SCHOEPFER, JOSEPH
To: NOVARTIS PHARMA AG
Reel/Frame 034184/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 034184/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: JAHNKE, WOLFGANG
To: NOVARTIS PHARMA AG
Reel/Frame 034184/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: NOVARTIS PHARMA AG
To: NOVARITS AG
Reel/Frame 034184/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2014
From: FURET, PASCAL; MANLEY, PAUL W.; MARZINZIK, ANDREAS; SCHOEPFER, JOSEPH; GROTZFELD, ROBERT MARTIN; JONES, DARRYL BRYNLEY; PELLE, XAVIER FRANCOIS ANDRE; SALEM, BAHAA
To: NOVARTIS PHARMA AG
Reel/Frame 034255/0359 →
Continuity (3)
Provisional Application 61789842 · Mar 15, 2013
Provisional Application 61647174 · May 15, 2012
Related Publication 20150126485A1 · May 7, 2015